Brigatanib Demonstrates Activity, Acceptable Safety Profile in ALK-rearranged NSCLC

Share this content:
Among patients with ALK-rearranged non-small cell lung cancer, brigatinib demonstrates clinical activity and an acceptable safety profile.
Among patients with ALK-rearranged non-small cell lung cancer, brigatinib demonstrates clinical activity and an acceptable safety profile.

Among patients with ALK-rearranged non-small cell lung cancer (NSCLC) who have been treated with crizotinib or are crizotinib-naive, brigatinib demonstrates clinical activity and an acceptable safety profile, according to a study published in The Lancet Oncology.1

Researchers conducted a phase 1/2 trial of 137 patients with NSCLC, 79 of whom had advanced malignancies such as ALK-rearranged NSCLC.

All 4 patients with ALK inhibitor-naive ALK-rearranged NSCLC had an objective response, as did 31 out of 42 patients with crizotinib-treated ALK-rearranged NSCLC, and 3 out of 18 patients who had other types of cancer with abnormalities in brigatinib targets.

Three out of 6 patients who had crizotinib-naive or crizotinib-treated ALK-rearranged NSCLC and active central nervous system metastases also had an objective response, and 3 patients within the same group had intracranial response.

RELATED: Cabozantinib ± Erlotinib May Be Superior to Erlotinib Alone in EGFR Wild-type NSCLC

Among 8 patients with crizotinib-naive ALK-rearranged NSCLC, all had a confirmed objective response.

Across all dosage levels, increased lipase concentration, dyspnea, and hypertension were the most common grade 3 to 4 treatment-emergent adverse events. Serious adverse events found in at least 5% of patients were dyspnea, pneumonia, and hypoxia.

Reference

  1. Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Nov 7. doi: 10.1016/S1470-2045(16)30392-8 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters